Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
5.39
-0.28 (-4.94%)
Apr 1, 2025, 4:00 PM EST - Market closed

Serina Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-11.145.27-2.68-1.26
Depreciation & Amortization
0.190.090.060.03
Other Amortization
0.35---
Loss (Gain) From Sale of Assets
--0-0.03
Loss (Gain) From Sale of Investments
--0.010.01
Stock-Based Compensation
2.60.030.010.08
Other Operating Activities
-5.81-7.940.54-0.33
Change in Accounts Receivable
--01.27
Change in Accounts Payable
-1.660.39-0-0.37
Change in Unearned Revenue
0.07-0.15-1.61
Change in Other Net Operating Assets
-1.72-0.31-0.16-0.05
Operating Cash Flow
-17.14-2.48-2.08-2.25
Capital Expenditures
-0.02-0.5-0.01-0.08
Investment in Securities
--0.990.93
Investing Cash Flow
-0.02-0.50.980.82
Long-Term Debt Issued
3.0410.15-
Long-Term Debt Repaid
-0.17-0.05-3.69-0.01
Net Debt Issued (Repaid)
2.8810.051.31-0.01
Issuance of Common Stock
100.0201
Other Financing Activities
0.34---
Financing Cash Flow
13.2110.071.311.08
Net Cash Flow
-3.957.090.22-0.35
Free Cash Flow
-17.16-2.98-2.09-2.34
Free Cash Flow Margin
-30641.07%-94.51%-352.55%-67.41%
Free Cash Flow Per Share
-2.33-0.74-0.97-1.09
Cash Interest Paid
--0.020
Levered Free Cash Flow
-7.94-0.82-1.22-
Unlevered Free Cash Flow
-7.96-0.48-1.21-
Change in Net Working Capital
0.99-0.87-0.15-
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q